中国当代医药Issue(23)：96-98,3.
碳酸镧联合阿法骨化醇治疗维持性腹膜透析患者继发甲状旁腺功能亢进的临床效果观察
Clinical effect observation of lanthanum carbonate combined with alpha-calcidol in the treatment of continuous peritoneal dialysis patients with secondary hyperparathyroidism
摘要
Abstract
Objective To observe the effect of lanthanum carbonate combined with alphacalcidol in the treatment of continuous peritoneal dialysis patients with secondary hyperparathyroidism. Methods 30 cases of continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism were selected and randomly divided into control group (n=15,alphacalcidol 0.5 μg/d)and treatment group (n=15,alphacalcidol 0.5 μg/d+lanthanum carbonate 500 mg,three times a day).In 3 months of treatment,serum calcium (Ca2+),serum phosphate (P3+)and serum intact parathyroid hormone (iPTH)was observed respectively. Results After 2 and 3 months of treatment in control group,only the level of serum Ca2+increased obviously between before and after treatment,with statistical difference (P<0.05).There was no statistical difference in the change of serum P3+and iPTH (P>0.05)in control group.In treatment group,serum P3+began to fall evi-dently after 1 month of combination therapy with lanthanum carbonate(P<0.05).Serum Ca2+and iPTH showed significant change after 2 month of treatment(P<0.05).There was statistical difference on the serum P3+and iPTH between treatment group and control group after 3 months respectively(P<0.05). Conclusion Alphacalcidol combined lanthanum carbonate can obviously improve the calcium and phosphorus metabolism disorder in peritoneal dialysis patients,and relieve sec-ondary hyperparathyroidism effectively.关键词
阿法骨化醇/碳酸镧/维持性腹膜透析/甲状旁腺功能亢进Key words
Alphacalcidol/Lanthanum carbonate/Continous peritoneal dialysis/Hyperparathyroidism分类
医药卫生引用本文复制引用
吴静,宋新灵,杨霞,陈爽,冉燕,査艳..碳酸镧联合阿法骨化醇治疗维持性腹膜透析患者继发甲状旁腺功能亢进的临床效果观察[J].中国当代医药,2014,(23):96-98,3.基金项目
贵州省科技厅-省人民医院联合基金项目（黔科合LS字[2012]037号）；贵州省卫生厅科学技术基金项目（黔科合J字[2012]2173号）；贵州省省长基金[黔省专合字（2012）128号]；贵州省优秀青年科技人才培养对象专项资金 黔科合人字（2013）43号 （）
